

Gunderson Dettmer Advises ARMO BioSciences, Inc. on Initial Public Offering

Client News

January 30, 2018

Gunderson Dettmer advised ARMO BioSciences, Inc. on its initial public offering of 8,658,823 shares at the price to the public of \$17.00 per share for a total of \$147,199,991 in aggregate gross proceeds. Corporate partner Marcia Hatch, IPOs and equity capital markets partner Richard Blake, and associates Colin Coklin, Sogol Salari and Elaine Strand Sylvester led the team advising ARMO.

The underwriting syndicate included Jefferies, Leerink Partners, BMO Capital Markets and Baird.

ARMO, which trades on the Nasdaq under the ticker symbol “ARMO,” is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors.

Related People



Marcia A. Hatch
PARTNER
P +1 734 585 2220

Related Services

Public Companies

Public Companies/Public Offerings

Featured Insights

CLIENT NEWS

Anduril Announces Acquisition of Klas to Advance Tactical Edge Computing and Communications

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Prosus Leads US\$7.25M Financing of Zapia

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Latin American Fintech Clara Announces \$80 Million Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act